• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis.

作者信息

Shimony Shai, Rozental Alon, Bewersdorf Jan P, Goldberg Aaron D, Stein Eytan M, Grimshaw Alyssa A, Stone Richard M, DeAngelo Daniel J, Wolach Ofir, Stahl Maximilian

机构信息

Medical Oncology, Dana Farber Cancer Institute, Boston, Ma, USA; Rabin Medical Center, Petah Tikva, Israel and Sackler Medical School, Aviv.

Rabin Medical Center, Petah Tikva, Israel and Sackler Medical School, Aviv.

出版信息

Haematologica. 2022 Dec 1;107(12):2955-2960. doi: 10.3324/haematol.2022.281453.

DOI:10.3324/haematol.2022.281453
PMID:36453519
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9713559/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cab/9713559/25ea8f958029/1072955.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cab/9713559/fb0f271ae7eb/1072955.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cab/9713559/f5bbd6cb4d9e/1072955.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cab/9713559/25ea8f958029/1072955.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cab/9713559/fb0f271ae7eb/1072955.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cab/9713559/f5bbd6cb4d9e/1072955.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cab/9713559/25ea8f958029/1072955.fig3.jpg

相似文献

1
Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis.急性髓系白血病中维奈克拉联合治疗的研究——一项系统评价和荟萃分析
Haematologica. 2022 Dec 1;107(12):2955-2960. doi: 10.3324/haematol.2022.281453.
2
Venetoclax in acute myeloid leukemia.维奈托克治疗急性髓系白血病
Expert Opin Investig Drugs. 2023 Apr;32(4):271-276. doi: 10.1080/13543784.2023.2193679. Epub 2023 Mar 23.
3
Acute myeloid leukemia drug development in the post-venetoclax era.维奈托克时代后急性髓系白血病的药物研发
Am J Hematol. 2019 Sep;94(9):959-962. doi: 10.1002/ajh.25556. Epub 2019 Jun 25.
4
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.维奈克拉与阿扎胞苷联合用药是复发/难治性急性髓系白血病患者移植策略的有效过渡方案。
Ann Hematol. 2021 Apr;100(4):1111-1113. doi: 10.1007/s00277-020-04333-7. Epub 2020 Nov 11.
5
[Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].维奈托克联合阿扎胞苷治疗老年急性髓系白血病或髓系肉瘤：三例报告及文献综述
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):694-696. doi: 10.3760/cma.j.issn.0253-2727.2020.08.016.
6
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.老年急性髓系白血病患者的更多选择：维奈克拉联合小剂量阿糖胞苷。
Chin Clin Oncol. 2019 Oct;8(S1):S25. doi: 10.21037/cco.2019.09.03.
7
Is venetoclax the new backbone of acute myeloid leukaemia therapy?维奈克拉会成为急性髓系白血病治疗的新支柱吗？
Lancet Haematol. 2021 Aug;8(8):e536-e537. doi: 10.1016/S2352-3026(21)00205-2.
8
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.使用地西他滨/维奈克拉和达雷妥尤单抗治疗与治疗相关的急性髓系白血病及潜在的多发性骨髓瘤。
Ann Hematol. 2021 Jun;100(6):1637-1640. doi: 10.1007/s00277-021-04490-3. Epub 2021 Mar 13.
9
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?维奈托克联合去甲基化药物或小剂量阿糖胞苷治疗急性髓系白血病：闪光的都是金子吗？
Blood Cancer J. 2020 Jan 28;10(1):10. doi: 10.1038/s41408-020-0281-x.
10
To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia.活着就好，但活得精彩更好：维奈克拉联合疗法与急性髓系白血病患者的生活质量
Blood Cancer J. 2022 Apr 25;12(4):75. doi: 10.1038/s41408-022-00672-y.

引用本文的文献

1
Venetoclax combined chemotherapy versus chemotherapy alone for acute myeloid leukemia: a systematic review and meta-analysis.维奈托克联合化疗与单纯化疗治疗急性髓系白血病的系统评价和荟萃分析
Front Oncol. 2024 Mar 26;14:1361988. doi: 10.3389/fonc.2024.1361988. eCollection 2024.
2
Venetoclax: A Game Changer in the Treatment of Younger AML Patients?维奈托克：年轻急性髓系白血病患者治疗的变革者？
Cancers (Basel). 2023 Dec 22;16(1):73. doi: 10.3390/cancers16010073.

本文引用的文献

1
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.维奈托克联合 FLAG-IDA 诱导和巩固治疗新诊断的急性髓系白血病。
Am J Hematol. 2022 Aug;97(8):1035-1043. doi: 10.1002/ajh.26601. Epub 2022 May 30.
2
Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes.维奈托克联合疗法治疗急性髓系白血病和骨髓增生异常综合征。
Curr Opin Hematol. 2022 Mar 1;29(2):63-73. doi: 10.1097/MOH.0000000000000698.
3
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
5-阿扎胞苷和 venetoclax 后首次完全缓解的急性髓系白血病的异基因造血细胞移植：一项多中心回顾性研究。
Ann Hematol. 2022 Feb;101(2):379-387. doi: 10.1007/s00277-021-04693-8. Epub 2021 Oct 9.
4
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Venetoclax 联合克拉屈滨、伊达比星和阿糖胞苷强化化疗治疗初诊急性髓系白血病或高危骨髓增生异常综合征患者：来自单中心、单臂、2 期临床试验的一个队列研究。
Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7.
5
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.维奈托克联合 FLAG-IDA 诱导和巩固治疗新诊断和复发/难治性急性髓系白血病。
J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27.
6
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.《PRISMA 2020声明：报告系统评价的更新指南》
Syst Rev. 2021 Mar 29;10(1):89. doi: 10.1186/s13643-021-01626-4.
7
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Venetoclax 治疗复发/难治性 AML 的反应和生存的临床和分子预测因子。
Blood Adv. 2021 Mar 9;5(5):1552-1564. doi: 10.1182/bloodadvances.2020003734.
8
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
9
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.美国急性髓系白血病患者接受阿糖胞苷-蒽环类诱导化疗的治疗模式及临床结局
Blood Adv. 2020 Apr 28;4(8):1615-1623. doi: 10.1182/bloodadvances.2020001728.
10
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.依拉环素对比研究者选择的挽救治疗方案用于治疗复发/难治性急性髓系白血病的国际多中心 III 期随机研究。
J Clin Oncol. 2014 Jun 20;32(18):1919-26. doi: 10.1200/JCO.2013.52.8562. Epub 2014 May 19.